Please login to the form below

Not currently logged in
Email:
Password:

Genentech’s Sunil Agarwal joins rare disease firm

He will serve as chief medical officer at Ultragenyx

Dr Sunil Agarwal has left his senior role at Genentech to join rare disease specialist Ultragenyx Pharmaceutical as its chief medical officer.

Dr Agarwal was most recently global head of clinical development for immunology and infectious diseases, metabolism, neuroscience and ophthalmology at Genentech, which has been the biotech arm of Roche since its acquisition in 2009.

He spent just over 10 years at Genentech where his positions included senior VP for immunology and infectious diseases and VP for rheumatology.

In his new role at Ultragenyx Dr Agarwal will lead the California-based company's clinical operations, regulatory affairs and pharmacovigilance efforts as it advances its pipeline of orphan products for rare and ultra-rare diseases. These include KRN23, a drug in development for people who have low levels of phosphate in the blood.

Commenting on his appointment Dr Agarwal said: “To develop novel therapies for these patients who have no approved treatments and to help push the science forward in these rare genetic diseases is something I am thrilled to be a part of.”

25th July 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics